GM00372
Fibroblast from Skin, Arm
Description:
GAUCHER DISEASE, TYPE I
GLUCOSIDASE, ACID BETA; GBA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Biopsy Source
|
Arm
|
Cell Type
|
Fibroblast
|
Tissue Type
|
Skin
|
Transformant
|
Untransformed
|
Sample Source
|
Fibroblast from Skin, Arm
|
Race
|
White
|
Country of Origin
|
USA
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
PDL at Freeze |
4.47 |
Passage Frozen |
6 |
|
MUTATION VERIFICATION |
Reiner et al (DNA 7:107-116 1988) employed a glucocerebrosidase cDNA in a Northern blot analysis to show that the mRNA from this type III Gaucher disease patient had the same three RNA species (6 2.6 & 2.2 kb transcripts) as found in normal placenta. Wigderson et al (Am J Hum Genet 44:365-377 1989) characterized the human glucocerebrosidase gene from Gaucher disease patients. The results obtained with DNA from this cell culture showed this patient to be heterozygous for a mutant allele. The mutant allele has a T to C transition at codon 444 that causes a substitution of proline for leucine and creates a new NciI restriction site. |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin confirmed by LINE assay |
|
glucosylceramidase |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.2.1.45; 6% activity. |
|
Gene |
GBA |
Chromosomal Location |
1q21 |
Allelic Variant 1 |
606463.0003; GAUCHER DISEASE, TYPE I |
Identified Mutation |
ASN370SER; By nucleotide sequence analysis of a genomic clone from an Ashkenazi Jewish patient with type I, Tsuji et al. [Proc. Nat. Acad. Sci. 85: 2349-2352 (1988] found a single-base mutation (adenosine to guanosine transition) in exon 9 of the glucocerebrosidase gene. This change resulted in the amino acid substitution of serine for asparagine. Transient expression studies following oligonucleotide-directed mutagenesis of the normal cDNA confirmed that the mutation results in loss of glucocerebrosidase activity. This mutation [1226G (N370S)] accounts for approximately 70% of mutations in the Jewish population. |
|
Gene |
GBA |
Chromosomal Location |
1q21 |
Allelic Variant 2 |
606463.0014; GAUCHER DISEASE, TYPE I |
Identified Mutation |
1-BP INS, 84G; Beutler et al. [Proc. Nat. Acad. Sci. 88: 10544-10547 (1991)] found a second common Jewish Gaucher disease mutation in addition to the A-to-G mutation of nucleotide 1226, which accounts for about 75% of mutant alleles in Ashkenazi Jews (606463.0003). The new mutation consisted of insertion of a second guanine at cDNA nucleotide 84 and was referred to as the 84GG mutation. The 84GG and A1226G mutations, along with the less-common mutation at nucleotide 1448 (606463.0001), account for 95% of all Gaucher disease-producing alleles in Ashkenazi Jews. |
Remarks |
Clinically affected; varying percentages of glucocerebrosidase activity (6%, 11.1%), B-glucosidase activity(4.1%, 16.1%), and glucosylsphingosine activity(9.6%) in this cell line have been reported in several publications - please refer to the publications tab on this sample page for more info; donor subject is a compound heterozygote for mutations in the gene encoding acid-beta glucosidase (GBA): one allele carries a single-base mutation (adenosine to guanosine transition) in exon 9 at position 1226 (1226A>G)of the glucocerebrosidase gene which results in the amino acid substitution of serine for asparagine [Asn370Ser (N370S)]; the second allele carries an insertion of a second guanine at cDNA nucleotide 84 (84GG). |
Tuyaa-Boustugue P, Jantzen I, Zhang H, Young SP, Broqua P, Tallandier M, Entchev E, Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models Molecular genetics and metabolism reports37:101011 2023 |
PubMed ID: 38053941 |
|
Akiyama T, Sato S, Ko SBH, Sano O, Sato S, Saito M, Nagai H, Ko MSH, Iwata H, Synthetic mRNA-based differentiation method enables early detection of Parkinson's phenotypes in neurons derived from Gaucher disease-induced pluripotent stem cells Stem cells translational medicine37:101011 2020 |
PubMed ID: 33342090 |
|
Zheng J, Jeon S, Jiang W, Burbulla LF, Ysselstein D, Oevel K, Krainc D, Silverman RB, Conversion of Quinazoline Modulators from Inhibitors to Activators of ß-Glucocerebrosidase Journal of medicinal chemistry37:101011 2019 |
PubMed ID: 30645117 |
|
Fog CK, Zago P, Malini E, Solanko LM, Peruzzo P, Bornaes C, Magnoni R, Mehmedbasic A, Petersen NHT, Bembi B, Aerts JFMG, Dardis A, Kirkegaard T, The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase EBioMedicine38:142-153 2018 |
PubMed ID: 30497978 |
|
Cheng WC, Weng CY, Yun WY, Chang SY, Lin YC, Tsai FJ, Huang FY, Chen YR., Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease. Bioorg Med Chem.21(17):5021-8 2013 |
PubMed ID: 23880081 |
|
Sasagasako N, Kobayashi T, Yamaguchi Y, Shinnoh N, Goto I, Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity. J Biochem (Tokyo)115:113-9 1994 |
PubMed ID: 8188616 |
|
Wigderson M, Firon N, Horowitz Z, Wilder S, Frishberg Y, Reiner O, Horowitz M, Characterization of mutations in Gaucher patients by cDNA cloning. Am J Hum Genet44:365-77 1989 |
PubMed ID: 2464926 |
|
Reiner O, Wigderson M, Horowitz M, Structural analysis of the human glucocerebrosidase genes. DNA7:107-16 1988 |
PubMed ID: 3359914 |
|
Reiner O, Wilder S, Givol D, Horowitz M, Efficient in vitro and in vivo expression of human glucocerebrosidase cDNA. DNA6:101-8 1987 |
PubMed ID: 2438102 |
|
Beutler E, Kuhl W, Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with type I, type II, and type III Gaucher disease. Proc Natl Acad Sci U S A83:7472-4 1986 |
PubMed ID: 3463977 |
|
Beutler E, Kuhl W, Sorge J, Cross-reacting material in Gaucher disease fibroblasts. Proc Natl Acad Sci U S A81:6506-10 1984 |
PubMed ID: 6593712 |
|
Choy FY, Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts. Hum Genet67:432-6 1984 |
PubMed ID: 6436168 |
dbSNP |
dbSNP ID: 10334 |
Gene Cards |
GBA |
Gene Ontology |
GO:0004348 glucosylceramidase activity |
|
GO:0005764 lysosome |
|
GO:0005975 carbohydrate metabolism |
|
GO:0006665 sphingolipid metabolism |
|
GO:0007040 lysosome organization and biogenesis |
|
GO:0016020 membrane |
|
GO:0016798 hydrolase activity, acting on glycosyl bonds |
NCBI Gene |
Gene ID:2629 |
|
Gene ID:2630 |
NCBI GTR |
230800 GAUCHER DISEASE, TYPE I; GD1 |
|
606463 GLUCOSIDASE, BETA, ACID; GBA |
OMIM |
230800 GAUCHER DISEASE, TYPE I; GD1 |
|
606463 GLUCOSIDASE, BETA, ACID; GBA |
Omim Description |
ACID BETA-GLUCOSIDASE DEFICIENCY |
|
GAUCHER DISEASE, NONCEREBRAL JUVENILE |
|
GAUCHER DISEASE, TYPE I |
|
GBA DEFICIENCYGLUCOSIDASE, ACID BETA, INCLUDED; GBA, INCLUDED |
|
GD I |
|
GLUCOCEREBROSIDASE DEFICIENCY |
|
GLUCOCEREBROSIDASE PSEUDOGENE, INCLUDED; GBAP, INCLUDED |
Passage Frozen |
6 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Supplement |
- |
|
|